Don’t miss out - Get your tickets early!

Join this FREE WEBINAR presented by Dr Louise Hecker (USA) and Dr Macsue Jacques.

TOPIC: Psilocybin For Longevity: From Discovery To Clinical Trials

This webinar will continue to examine psilocybin research through a geroscience and systems biology lens, focusing on what psychedelic-induced distress can reveal about fundamental ageing processes across biological systems and how and why psilocybin may improve human life and health span.

Key Learning Outcomes:

Learn about new research discoveries that suggest psilocybin impacts ageing
Learn about the previously unexplored systemic impacts of psilocybin on organ health
Learn about the potential of psilocybin for delaying the onset of age-associated diseases
Hear about the first clinical trial to evaluate the impacts of psilocybin on healthy aging

EVENT DETAILS

DATE: 10th November 2027
TIME: 11:55am (AEDT) for 12:00pm start, finishing at 1:15pm
DURATION: 75 minutes (incl Q&A)
LOCATION: Online - a link will be emailed to you with the viewing details

A replay of the event will be made available on our YouTube channel.

ABOUT THE PRESENTERS

Dr Louise Hecker (USA)
PhD
Clinical Associate Professor: Medicine - Cardiovascular Research, Baylor College of Medicine

Louise Hecker, PhD is an Associate Professor at Baylor College of Medicine and the Founder and Chief Scientific Officer at Fibronox with over 15 years of experience in regenerative biology, fibrosis research, and age-related disease therapeutics. She is a world-leading expert on Nox4 and Nrf2, having made numerous seminal discoveries in understanding how oxidative stress contributes to tissue fibrosis and aging.

Her groundbreaking research has revolutionized the understanding of fibrotic diseases and recently expanded into psychedelic medicine, where her team discovered that psilocybin extends cellular lifespan by up to 57% and improves survival in aged mice. As an academic entrepreneur, she has founded five companies and secured approximately $15 million in research funding as Principal Investigator while holding around 20 patent applications.

Dr Macsue Jacques
PhD
Postdoctoral Researcher at Monash University

Dr Macsue Jacques is a prominent postdoctoral researcher and data scientist specializing in aging, epigenetics, and longevity science. Based at the Australian Regenerative Medicine Institute (ARMI) at Monash University, she focuses on utilizing multi-omics approaches and advanced computational tools to understand the mechanisms of aging.

---

MEDICINAL PSYCHEDELIC TREATMENTS

Psychedelic-assisted treatments offer enormous potential in providing a meaningful alternative to current treatments for mental illness. PTSD is a debilitating condition that affects tens of millions of people worldwide, with many more trauma victims diagnosed with comorbid conditions such as depression, anxiety and eating disorders. In recent clinical trials, MDMA has been shown to produce reliable clinical improvements, restoring patient safety and self-agency even for individuals who have suffered with PTSD for many years, and for whom many treatments have failed.

The wave of clinical psychedelic research and regulatory support is rapidly building, with experts forecasting the availability of psychedelic-assisted treatments in the US and EU within the next 2 to 5 years, subject to positive clinical outcomes in large trials that are currently underway.

SUPPORT PSYCHEDELIC RESEARCH AND THERAPY DEVELOPMENT

Your donation to Mind Medicine Australia will help us accelerate the availability and best practice of psychedelic-assisted psychotherapy in Australia. We are a small organisation doing big things – we need your support. Please click here to make a tax-deductible donation.

DISCLAIMER

Mind Medicine Australia does not encourage or facilitate illegal use of psychedelics or plant medicines. MMA is focused on clinical and legal use only supported by the emerging science and legislative processes. Mind Medicine Australia reserves the right to record and publish webinars on various social media platforms. You agree that you will not discuss any names, locations or specific details of illegal use of psychedelics both verbally or via any written forms of communication via Mind Medicine Australia social media platforms i.e. Facebook, Instagram or zoom private and public chat forms during the webinar. Breaches of these guidelines may result in not being able to participate in the event. We thank you for your support and cooperation on these matters. Mind Medicine Australia is focused specifically on the clinical application of medicinal psilocybin and medicinal MDMA for certain mental illnesses.

Contact the host of Mind Medicine Australia FREE Webinar: Psilocybin For Longevity: From Discovery To Clinical Trials with Dr Louise Hecker (USA) and Dr Macsue Jacques

There were 0 errors found in the information you submitted: